Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

ConditionsR/R B-NHL Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (R/R B-NHL)

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-78

SponsorDonghua Zhang

About this trial

Evaluate the safety and tolerability of AcNK-Sup003 cell injection in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). To preliminarily determine the Maximum Tolerated Dose (MTD) or recommended clinical dose of AcNK-Sup003 cell injection.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Single group

Treatments tested in this trial

AcNK-Sup003 cell injection
Drug
AcNK-Sup003 cell injection in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL)

Treatment groups

28 Participants

are divided into 1 treatment group

Group A: Experimental:Experimental groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Overall survival

Time frame:1, 3,6,12,18, 24 months after treatment

Time frame

Time frame:1, 3,6,12,18, 24 months after treatment

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Donghua Zhang

Lead sponsor

Tongji Hospital

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: